The Research in Your Backyard Report shows how biopharmaceutical research companies continue to be vitally important to the economy and patient health in Nebraska.
Today at the ACS CAN Nebraska Cancer Research Forum, PhRMA announced the release of their 2021 Research in Your Backyard report. The report shows how biopharmaceutical research companies continue to be vitally important to the economy and patient health in Nebraska.
“Clinical trials are an essential component of today’s healthcare system,” Rob Owen, Executive Director of Bio Nebraska, said in the report. “This report illustrates that not only are clinical trials important to improving patient care and the lives of Nebraskans and citizens across the world, but have a significant impact on Nebraska’s economy with a total economic impact of $394 million. With more than 3,400 clinical trials being held in Nebraska since 2004, we should be proud of Nebraska’s contribution to providing cutting-edge care to patients.”
Since 2004, biopharmaceutical research companies have conducted or are conducting more than 3,400 clinical trials of new medicines in Nebraska in collaboration with clinical research centers, hospitals and local research institutions. These clinical trials have investigated or are investigating some of Nebraska’s biggest health care challenges, including asthma, arthritis, cancer, diabetes, cardiovascular disease and gastrointestinal diseases. Currently, there are 394 open clinical trials in Nebraska including 179 addressing cancer, 57 on infectious disease and 24 on cardiovascular disease.